Title of article
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial
Author/Authors
Thomas J Schnitzer، نويسنده , , Gerd R Burmester، نويسنده , , Eduardo Mysler، نويسنده , , Marc C. Hochberg، نويسنده , , MICHAEL DOHERTY، نويسنده , , Elena Ehrsam، نويسنده , , Xavier Gitton، نويسنده , , Gerhard Krammer، نويسنده , , Bernhard Mellein، نويسنده , , Patrice Matchaba، نويسنده , , Alberto Gimona، نويسنده , , Christopher J. Hawkey، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2004
Pages
10
From page
665
To page
674
Abstract
Background
Cyclo-oxygenase 2 (COX2)-selective inhibitors should reduce ulcer complications compared with non-selective non-steroidal anti-inflammatory drugs, but evidence is limited, and the possibility that these inhibitors increase cardiovascular events
Journal title
The Lancet
Serial Year
2004
Journal title
The Lancet
Record number
586877
Link To Document